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Abstract
Pollen is the most common aeroallergen to cause seasonal conjunctivitis. The result of allergen exposure is a strong Th2-
mediated response along with conjunctival mast cell degranulation and eosinophilic infiltration. Oleanolic acid (OA) is
natural a triterpene that displays strong anti-inflammatory and immunomodulatory properties being an active anti-allergic
molecule on hypersensitivity reaction models. However, its effect on inflammatory ocular disorders including conjunctivits,
has not yet been addressed. Hence, using a Ragweed pollen (RWP)-specific allergic conjunctivitis (EAC) mouse model we
study here whether OA could modify responses associated to allergic processes. We found that OA treatment restricted
mast cell degranulation and infiltration of eosinophils in conjunctival tissue and decreased allergen-specific Igs levels in EAC
mice. Th2-type cytokines, secreted phospholipase A2 type-IIA (sPLA2-IIA), and chemokines levels were also significantly
diminished in the conjunctiva and serum of OA-treated EAC mice. Moreover, OA treatment also suppressed RWP-specific T-
cell proliferation. In vitro studies, on relevant cells of the allergic process, revealed that OA reduced the proliferative and
migratory response, as well as the synthesis of proinflammatory mediators on EoL-1 eosinophils and RBL-2H3 mast cells
exposed to allergic and/or crucial inflammatory stimuli such as RWP, sPLA2-IIA or eotaxin. Taken together, these findings
demonstrate the beneficial activity of OA in ocular allergic processes and may provide a new intervention strategy and
potential therapy for allergic diseases.
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Introduction
Allergic conjunctivitis (AC) is one of the most common ocular
surface diseases. The disease encompasses a variety of pathological
conditions, and based on immunopathological mechanisms, it can
be subdivided into seasonal and perennial allergic conjunctivitis
[1]. AC is an abnormal immune-hypersensitivity response to
allergens mainly pollen, animal dander and house dust mites,
although some food substances may also trigger it. They have
common immunopathogenic mechanisms characterized by IgE-
mediated mast cell degranulation and/or T-lymphocyte-mediated
immune response. Allergen-specific Th2-type lymphocytes play
important roles in the immunopathophysiology of allergic
disorders because of their ability to produce IL-4, IL-5 and IL-
13, which are involved in IgE production and eosinophil activation
[2].
Medications for AC include drug treatment (anti-histamines,
mast cell stabilizers, corticosteroids, non-steroidal anti-inflamma-
tories, immunomodulatories), and allergen-specific immunothera-
py. However, its effectiveness can be endangered by adherence
problems related to factors, such as discomfort associated with
treatment administration, complexity of administration guidelines,
perception of a lack of efficacy at treatment initiation, and/or
adverse effects. Therefore, the development of new therapeutic
strategies will be a valuable tool to achieve better control of the
disease and, thus, will improve healthcare outcome for patients
with allergic conjunctivitis.
Because alternative treatments are needed, plants and other
natural materials may prove to be valuable sources of useful new
anti-allergic agents [3]. Research groups have conducted clinical
trials with remedies from complementary and alternative medicine
[4–7]. Plant formulations have demonstrated, in general, to be
safe, revealing additional effects along with Western medicines
such as synergism and modulation of the immune system.
Triterpenes, including oleanolic acid (OA) are compounds that
widely exist in the human diet, medicinal herbs and plants. OA
has been identified in more than 120 plant species, including olea
europaea, a plant that has gained more and more interest because of
its multiple bioactive components [8]. Among the numerous
beneficial effects, OA has been shown to have cardioprotective,
antihypertensive, antiatherosclerotic, antihyperlipidemic and anti-
oxidant activities, among other, as well as anti-inflammatory and
immunomodulatory properties, being active on hypersensitivity
reactions, such as the delayed-type hypersensitivity reaction, or
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allergic asthma, and in Th1-mediated diseases, including exper-
imental colitis and multiple sclerosis [9–16]. However, the
effectiveness of OA in the treatment of ocular diseases such as
allergic conjunctivitis is still unknown.
The IgE-mediated conjunctival allergic reaction can be
reproduced easily in mice by using RWP as antigen [17]. The
result is an early reaction followed by a predominant infiltration of
eosinophilic inflammatory cells, which are the hallmark of allergic
disease, and mast cell activation. This experimental allergic
conjunctivitis (EAC) model mimics the pathological symptoms of
AC in human, being a valuable tool to understand the
pathogenesis of the disease, as well as for new drugs evaluation.
The aim of this study was, therefore, to evaluate the effectiveness
of OA using this well-characterized EAC model induced by RWP
in BALB/c mice.
Materials and Methods
Disease Induction and Treatment
Animal care and experimental protocols were reviewed and
approved by the Animal Ethics Committee of the University of
Valladolid and complied the standards in the ARVO Statement.
Mice (Charles River Laboratories, Barcelona, Spain) were housed
in the animal facilities of the University of Valladolid and provided
food and water ad libitum.
Immunization. EAC was induced in 6- to 7-week-old
females BALB/c mice by intraperitoneal (i.p.) sensitization with
200 ml from a mixture of 50 mg RWP (Polyscience, Warrington,
PA) in 0.25 ml Imject Alum (Thermo Scienctific, Rockford, IL).
Then, on day 10, mice were topically instilled into each eye with
1.25 mg of RWP in powder form [3,18]. Twenty-four hours later,
eyes, blood and spleens were collected.
Treatment. Oleanolic acid (Extrasynthese, Genay Cedex,
France) was dissolved in 2% w/v DMSO. Then, this stock solution
was 10 times diluted to a working concentration of 2 mg/ml
(0.2%, w/v DMSO final concentration), using a sterile saline
solution (pre-warmed to 37uC) with mild shaking. Always, OA
working solution was prepared fresh the day of the injection and
sterile-filtered through a 0.22 mm filter. OA (50 mg/kg body
weight/day) was administered i.p. once a day from sensitization
day (OA10) or 5 days after sensitization (OA5) as shown in
Figure 1B (n = 10 per group). The molecular structure of OA is
shown in Fig. 1A (OA molecular formula: C30H48O3, molecular
weight: 456.70).
Evaluation of Cell Infiltration
Eyes including eyelids and conjunctiva were exenterated and
fixed in 4% paraformaldehyde for 24 h. Then, they were cut into
cross sections 3-mm thick and stained with toluidine blue and
hematoxylin-eosine for detection of mast cells and eosinophils,
respectively. In each section, infiltrating cells in the lamina propria
mucosae of the palpebral and bulbar conjunctivas were counted
by two masked observers. Palpebral zone: connective tissue
between the epithelium and the Meibomio gland in the centre
of the lid. Bulbar conjunctiva: near the cornea in reflection zone
that form the conjunctival sac. In each slide there were two non-
consecutive sections and three slides per eye and per stain were
counted. An Olympus B–H (Olympus optical Co. LTD, Tokio,
Japan) microscope and a micrometer ocular grid were used to
evaluate the slides (magnification x400). Data are presented as
mean 6 SD per mm2.
Cytokines, Chemokines and RWP-specific Igs
Quantitation
Serum was aliquoted and stored at 280uC. Immunoplates
(Nalge Nunc International, Naperville, IL) were coated with RWP
(5 mg/ml) overnight at 4uC. After blocking with 1% BSA-PBS for
2 h, serum samples diluted 1:60 were added and incubated for
3 h. After washing, plates were incubated for 1 h with horseradish
peroxidase-conjugated rat anti-mouse IgE, IgG, IgG1 or IgG2a
antibodies (1:2000) from Serotec (Sigma-Aldrich, St Louis, MO).
Color reaction was developed with 3,39,5,59-tetramethyl-benzidine
and stopped with 0.1N HCl. Data are expressed as mean optical
density (OD) at 450 nm.
For cytokine and chemokine quantification - IL-10, IL-13, IL-
33, monocyte chemoattractant protein-1 (MCP-1) and eotaxin -
cell culture medium, serum and conjunctival tissue were analyzed
by ELISA according to the manufacturer’s protocols (eBioscience,
San Diego, CA). Secreted phospholipase A2-typeIIA (sPLA2-IIA)
levels were determined by commercial ELISA (USCNK Life
Science Inc, Houston, TX). Conjunctival tissue was homogenized
by using a tissue homogenizer (Cole-Parmer Instrument, Vernon
Hills, IL) in an ice bath in 0.5 ml ice-cold PBS supplemented with
0.4 M NaCl, 0.05% Tween-20 and a protease inhibitor cocktail:
20 mg/ml of leupeptin, 20 KI units of aprotinin, 0.1 mM
phenylmethylsulphonyl fluoride, and centrifuged for 10 min at
4uC. Supernatant were stored at 280uC until cytokine assays were
performed. Total protein was assayed using the Bradford method.
Ex vivo Lymphoid Cell Culture and Analysis of
Proliferation and Cytokine Production
To prepared single cell suspension, spleens were pressed though
a wire mesh and then washed with ice-cold PBS. Red blood cells-
depleted splenocytes (106106 cells/ml) were cultured in triplicate
in 96-well plates, and stimulated with medium alone or with
50 mg/ml of RWP in presence or absence of different doses of OA.
After 24 h, supernatants were harvested and concentrations of IL-
33, IL-13 and MCP-1 were measured. Cells were prepared for
proliferation analyses using the Promega kit, Cell Titer 96RAqu-
eous One Solution Cell Proliferation Assay (Promega Corporation,
Madison, WI), according to the manufacturer’s recommendations.
Formazan product formation was determined by measuring the
absorbance at 490 nm. Results were expressed as OD values, as an
assessment of the number of metabolically active cells.
In vitro Studies
Cell culture. The rat basophilic leukemia (RBL) mast cell line
RBL-2H3 (kindly provided by Dr. Ruiz; Hospital Universitario
Puerta del Mar, Facultad de Medicina, Universidad de Ca´diz,
Spain) was grown in EMEM supplemented with 15% heat-
inactivated FCS, 0.1 mM nonessential amino acids, 50 U/ml
penicillin, and 50 mg/ml streptomycin [19].
The human eosinophilic cell line EoL-1 (kindly provided by Dr.
Wicklein, University Medical-Center Hamburg-Eppendorf, Ham-
burg, Germany) was grown in RPMI 1640 medium, supplemented
with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin [20,21].
Both cell lines were cultured in standard conditions (37uC and
5% CO2).
Proliferation assay. The proliferative activity of EoL-1 and
RBL-2H3 cells was quantified using the Promega kit, Cell Titer
96RAqueous One Solution Cell Proliferation Assay, as described
for the ex vivo proliferation assay. In brief, cells (16105 cells/ml)
were serum-starved for 24 h, incubated as indicated and
measured. Results were expressed as OD values.
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Chemotaxis assay. Cell migration was assayed using 24-
well Transwell chambers with 8 mm-pore polycarbonate filters.
Lower wells were filled with medium containing eotaxin, sPLA2-
IIA or vehicle, as indicated. Cells (16106 cells/ml) were added to
the upper chamber. When indicated, cells were treated with
sPLA2-IIA, RWP or OA for 20 min at 37uC before seeding.
Migration was allowed for 3–4 h at 37uC in 5% CO2. Migrated
RHL-2H3 cells were fixed with 4% paraformaldehyde and
stained with 0.1% Crystal Violet in 20% methanol-PBS for 3
minutes. The stain was solubilized and absorbance measured at
590 nm. Migrated EoL-1 cells were quantified by flow cytometry
analysis. Chemotactic index was calculated from the number of
cells migrating towards chemoatractant/number of cells migrat-
ing towards vehicle control.
Flow cytometry of intracellular major basic protein
(MBP). EoL-1 cells were treated with butyric acid, or the
stimuli eotaxin, RWP, sPLA2-IIA or combinations for 7 days.
Then, cells were washed with 0.5% BSA-PBS, fixed with 4%
paraformaldehyde for 30 min and permeabilized with 0.2%
Triton-X 100 in PBS for 10 min. Non-specific antibody binding
was blocked by incubating cells with normal mouse IgG for
30 min. Then, cells were stained with an anti-MBP antibody
(1:200) for 2 h. After washing, they were incubated with FITC-
labeled goat anti-mouse IgG for 1 h at 4uC. Baseline fluorescence
values were obtained by incubation with isotype mouse IgG
antibody. After washing, the stained cells were analyzed using a
Gallios Flow cytometer (Beckman Coulter), and acquisition and
analysis were performed using CellQuest software. The data are
presented as an average of mean intensity fluorescence (MIF).
Statistical Analysis
Statistical significance between groups was examined by one-
way ANOVA using the GraphPad Prism Version 4 software (San
Diego, CA). A post hoc analysis was made by the Bonferroni’s
multiple comparison test. P,0.05 was considered statistically
significant.
Figure 1. Reduction of circulating anti-RWP antibodies in OA-treated mice. Molecular structure of OA (A). Experimental protocol (B). BALB/c
mice were sensitized on day 0 via i.p. injection with RWP emulsified in aluminum hydroxide. 10 days latter, individual mice were challenged through
ocular instillation with RWP. OA was administered i.p. at the sensitization day (OA10) or 5 days after sensitization (OA5). Animals were sacrificed 24 h
after the challenge. (C) Titers of RWP-specific immunoglobulins in serum samples. *P,0.001 versus control, and **P,0.001 versus untreated EAC-
mice.
doi:10.1371/journal.pone.0091282.g001
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Results
OA Treatment Inhibits RWP-specific Antibody Production
in EAC Mice
To investigate whether OA treatment modulates adaptive
immune response to conjunctival allergens, as well as the influence
of the pre-treatment period in its effectiveness, EAC mice were
treated with OA from sensitization day (OA10) or 5 days after
sensitization (OA5) as shown in Figure 1B. The severity of EAC
was elucidated by assessing RWP-specific IgE antibody levels in
serum. The combination of systemic sensitization and local
boosting with RWP resulted in significantly higher levels of Ag-
specific IgE antibody secretion (Fig. 1C) compared with those in
normal mice. However, the administration of OA, both under
OA10 and OA5 protocols, led to a dramatic and similar reduction
of Ag-specific IgE antibody levels (Fig. 1C). To address overall
immunosuppression by OA, we also assessed levels of RWP-
specific IgG, IgG1 and IgG2a antibodies in serum, finding similar
results to those obtained for RWP-specific IgE antibodies. Taken
together, these data suggest that oleanolic acid suppressed both
allergen specific IgE production and overall immune responses.
OA Treatment Attenuates Cellular Infiltration into
Conjunctiva in EAC Mice
Histological findings demonstrated by toluidine blue staining
the presence of numerous mast cells infiltrating lamina propria
and stroma of conjunctiva in EAC mice, being most of them
degranulated mast cells (Fig. 2A and C). In contrast, in the OA-
treated EAC groups infiltrating mast cells were mainly granulated
and the number of degranulated mast cells was significant lower,
compared to untreated ones.
In the same way, hematoxylin-eosine staining revealed a
significant infiltration of eosinophils in the conjunctiva of RWP-
challenged mice 24 h after systemic priming (Fig. 2B and D).
Interestingly, the number of eosinophils infiltrating the conjunctiva
after allergen challenge was minimal in mice treated with OA.
Mast cell and eosinophil counts were not significantly different
between EAC mice injected with either oleanolic acid regimens
(OA10 or OA5).
OA Treatment Reduces the Release of EAC-associated
Cytokines and Chemokines
Th2-associated cytokines and chemokines are typically secreted
in allergic reactions. To evaluate the effect of OA on cytokine
secretion, levels of IL-13 and IL-33 were investigated in serum and
conjunctival tissue by commercial ELISAs. As shown in Figure 3 A
and B, IL-33 and IL-13 were remarkably up-regulated in the
allergic state and OA treatment diminished their expression levels.
We also evaluated the presence of IL-10, a known suppressive
cytokine of T-cell proliferation and cytokine production, in
normal, allergic and OA-treated allergic mice. We found that
IL-10 levels in serum and tissue were significantly diminished in
the allergic state, but were up-regulated reaching values of the
normal state, in OA-treated EAC mice.
Production and build up of sPLA2-IIA, an acute-phase reactant
associated with a number of inflammatory, autoimmune, and
allergic diseases, was also evaluated [22]. sPLA2-IIA was
augmented in serum and conjunctivas of mice from the
untreated-EAC group, compared with the healthy-control group
(Fig. 3 A and B). However, and according to Th2-type cytokines
data, we found that this inflammatory protein was significantly
lower in OA-treated EAC mice, at both systemic and local level.
Moreover, we also measured the concentration of two
chemokines: eotaxin, given its critical role in eosinophil recruit-
ment, Th2-related cytokines production and mast cell priming;
and MCP-1, which is essential for mast cell-mediated acute
inflammatory responses [23]. Again, we observed that OA
treatment suppressed the high levels of eotaxin and MCP-1 found
in sera and conjunctivas of allergic mice (Fig. 3 C and D).
There was no difference in regulating these conjunctivitis-
associated markers between the two treatment protocols: EACOA5
and EACOA10.
OA Treatment Regulates T Cell Responses in EAC
Next, to investigate whether OA treatment inhibits EAC by
modifying/affecting systemic immune responses, we evaluated the
function of splenocytes harvested from mice of the four
experimental groups.
Spleen cells were assessed for antigen-specific proliferation and
cytokine secretion after in vitro stimulation with RWP in the
presence or absence of different doses of OA. RWP-specific
proliferative response, as well as IL-13, IL-33 and MCP-1
production were significantly increased in spleen cells from mice
with EAC, and addition of OA markedly suppressed, in a dose-
dependent manner, these ex-vivo responses to the allergen (Fig. 4,
A and C). In contrast, splenocytes isolated from healthy-control
mice did not respond to in vitro RWP challenge, and no major
responses were detected in spleen cells from EACOA10 and
EACOA5 mice (Fig. 4, B and D).
OA Inhibits in vitro Functional Activation of Allergy-
related Cells
We next investigated whether the anti-inflammatory effect
found in vivo, in OA-treated EAC mice, comprises also direct
in vitro actions on cells particularly important for the development
of allergic disorders. Therefore, the well-characterized eosinophil
cell line EoL-1 and RBL-2H3 mast cells were used to mimic
responses activated on ocular allergic reactions.
Proliferation and survival. EoL-1 eosinophils and RBL-
2H3 mast cells were treated with different concentrations of RWP
or eotaxin in presence or absence of either 5 or 10 mM of OA for
24 h. As shown in Figure 5A and B, the presence of OA
significantly reduced, the proliferative response induced by the
agonists, in a dose-dependent manner. The presence of OA had
no significant influence on the viability of either resting or
activated cells.
Chemotactic migration. The capacity of OA to modulate
EoL-1 eosinophils and RBL-2H3 mast cells migration was assessed
using Transwell chambers. As shown in Fig. 5 C and D, cell
pretreatment with OA reduced in a dose-dependent manner the
chemotactic activity of eotaxin in both cell lines.
We also assessed the capacity of sPLA2-IIA, found up-regulated
in EAC mice, and RWP to elicit and/or modify chemotactic
migration. As schematically colored-indicated in Figure 6, sPLA2-
IIA added in the lower compartment of transwell chamber
induced a significant increase in EoL-1 eosinophils (Fig. 6A) and
RBL-2H3 mast cells (Fig. 6B) migration over controls. In addition,
both sPLA2-IIA- and RWP-cell pretreatment potently stimulated
both spontaneous and chemoattractant-induced cell migration.
Then, we investigated the effects of OA, and we observed that
cell migration was potently inhibited when cells were pre-
incubated with OA. Addition of OA to the lower chamber had
no detectable effect on cell motility (data not shown).
EoL-1 eosinophils differentiation. Differentiation of EoL-1
cells was triggered chemically with butyric acid, or with stimuli
such as eotaxin, RWP and sPLA2-IIA, and the expression of MBP,
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a mature eosinophil marker, was evaluated by flow cytometry. As
shown in Figure 7A all the agonists on their own promoted the
upregulation of MBP at day 7 after treatment. Interestingly, when
the agonists eotaxin, RWP, or sPLA2-IIA were added in
combination with butyric acid, the differentiation process was
significantly increased over butyric acid alone. As expected, the
presence of OA before incubation the cells with the agonists,
abrogated the differentiation process (Fig. 7B).
Discussion
OA is a powerful anti-inflammatory agent, whose activity in
ocular inflammatory disorders has never been investigated. Here,
we examined the effect of OA on allergic conjunctivitis in a RWP-
induced EAC model as well as its effects in vitro on eosinophils
and mast cells functions. We focused on these cells since they are
important mediators in the development of allergic diseases and
inflammatory processes.
Intraperitoneal administration of OA, either on the sensitization
day or 5 days after sensitization to an EAC model, provided strong
evidence of its anti-allergic effects; while, its administration to
healthy BALB/c mice did not induce signs of any pro-
inflammatory response (data not sown), as found in other
experimental mice models [14,15]. The main pathophysiological
changes in conjunctival allergic reactions include preferential
generation of IgE antibodies in serum, as well as IgE-dependent
mast cell degranulation and infiltration of eosinophils into the
conjunctiva [24]. Our mouse model displayed these pathological
hallmarks, and OA treatment effectively reduced the number of
eosinophils and degranulated mast cells in the conjunctival tissue,
and suppressed the presence of allergen-specific Igs titers in serum,
showing no remarkable difference in the degree of suppression of
these features between the two OA administration protocols.
These findings were consistent with the decreased levels of
inflammatory mediators and Th2 cytokine found in the OA-
treated mice (EACOA10 and EACOA5).
The pathological processes of an allergic reaction are thought to
be mediated by Th2-type cells which release interleukins such as
IL-5 and IL-13. These cytokines are responsible for a cascade of
events necessary for allergic inflammation: IgE production by B-
cells, eosinophil activation and recruitment, and mast cell
activation. IL-13 is a crucial mediator of hypersensivity reactions
[25–29]. Different studies in murine models of allergen challenge
have shown that IL-13 is a critical factor to induce responses that
have a striking resemblance to human diseases. IL-13 regulates
synthesis of IgE and coordinates the inflammatory process due to
its ability to stimulate expression of adhesion molecules, chemo-
kines and metalloproteinases, which influence the recruitment,
trafficking and activation of many inflammatory cells. Meanwhile,
IL-33 is another powerful inducer of allergic inflammation which
has been found highly expressed in Th2-associated diseases
including asthma, allergic conjunctivitis and rhinitis [30,31]. IL-
33 promotes responses which include activation and migration of
Th2 lymphocytes, eosinophils, mast cells and basophiles.
Our data clearly demonstrated that the expected increased
levels of IL-13, and IL-33 in the conjunctival tissue and serum of
EAC mice were markedly suppressed by OA treatment. Likewise,
we did see an allergen-induced increase in the release of these
cytokines in splenocytes cultures after allergen challenge. Treat-
Figure 2. OA administration prevents development of allergic conjunctival inflammation. Light micrograph of conjunctival sections in
mice from allergic untreated, OA5-treated and OA10-treated groups. Representative toluidine (A) and H-E (B) stained sections showed infiltration in
palpebral conjunctiva of mast cells and eosinophils, respectively. (C, D) Number of degranulated mast cells/mm2 and eosinophils/mm2, respectively.
In images, green bars = 50 mm. In inserts, red bars = 10 mm. * and **P,0.01 (n = 10, three independent experiments). Zone I: conjunctiva palpebral.
Zone II: conjunctiva bulbar. * and +P,0.001 versus control zone I and zone II, respectively; ** and ++P,0.001 versus untreated EAC-mice zone I and
zone II, respectively; and ***P,0.01 versus untreated EAC-mice zone I.
doi:10.1371/journal.pone.0091282.g002
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ment with OA, both in vivo and in vitro, significantly reduced IL-
13 and IL-33 cytokine production. Additionally, examination of
chemokine induction revealed that the upregulated levels of
eotaxin and MCP-1, in both serum and the conjunctiva of
sensitized mice after allergen challenge, were substantially
decreased in OA-treated mice. Similar results were found in vitro:
splenocytes from the different experimental groups also showed a
substantial reduction in the allergen-induced eotaxin and MCP-1
by the action of OA, along with a minimization of the proliferative
response of these T-cell cultures. All of this suggests that OA was
able not only to down-modulate both the systemic and local
allergen-induced inflammatory response, but also to impair
allergen-induced T cell responses in vivo and in vitro.
IL-13 has been shown to regulate the expression of MCP-1 and
eotaxin in the respiratory and gastrointestinal mucosa, and
exogenous application of IL-33 to an EAC model strongly induces
local production of the chemoattractant eotaxin, and potentiates
the capacity of Th2 cells to produce cytokines including IL-13
[30,32–36]. At the same time, eotaxin-1 is considered as the most
relevant chemokine in the pathophysiology of allergic conditions,
because of its contribution to eosinophil homing or allergen-
dependent chemoattraction and its regulatory function in mast
cells at the ocular tissue regulating both IgE-induced degranula-
tion and presumably maturation [30]. Therefore, the reduced
presence of eosinophils and degranulated mast cells, in the
conjunctiva of the OA-treated EAC mice treated, might be closely
linked to the decreased expression of IL-13, IL-33 and eotaxin, all
of which were clearly down-modulated by OA. Similarly, the
improvement of allergic conjunctivitis in mice subjected to
treatment with natural products such as curcumin or thymoqui-
nine, an anti-oxidant and anti-inflammatory active component of
Nigella sativa, has also been linked to its capacity to suppress Th2-
driven immune responses [37,38].
Another finding was that treatment of EAC mice with OA
prevented the diminished secretion of IL-10 observed in untreat-
ed-EAC mice. In fact, the expression levels in serum and
conjunctival tissue of this Treg-type cytokine involved in the
Th1/Th2 homeostasis were similar in OA-treated EAC mice and
in healthy control mice. It is noteworthy that in addition to its anti-
inflammatory properties on human mast cells, IL-10 has recently
been shown to stabilize murine mast cells and reduce their
degranulation in vitro [39,40]. Data which are in accordance with
an in vivo study in a rodent model, which report that IL-10
attenuates allergic conjunctivitis by protecting from mast cell
activation/degranulation, instead of affecting its numbers in the
conjunctiva [40]. Similarly, our study neither revealed significant
differences in the number of mast cells in the conjunctiva between
untreated- and OA-treated-EAC mice (data not shown), but rather
OA treatment prevented from mast cells degranulation.
In addition, we found an increased presence of sPLA2-IIA in
serum and conjunctiva of allergic mice as compared to control
healthy mice, and the administration of OA again abrogated this
augmented expression. High concentrations of sPLA2-IIA have
already been found in the tears of patients with AC both seasonal
and perennial, dry eye disease, chronic blepharitis and contact lens
intolerance, when compared to tears of age-matched normal
controls [41–43]. Recently, a dry eye experimental model in mice
has revealed increased expression of sPLA2-IIA in the goblet, as
well as in epithelial cells associated with the signs and symptoms of
the diseases [22]. sPLA2-IIA in the normal ocular surface was
shown to be an innate immune barrier of the ocular surface
against microbial infection, but when the ocular surface is
compromised, it amplifies the inflammatory process [22,43].
These findings might support the hypothesis that the elevated
levels of sPLA2-IIA on conjunctiva of our EAC model might play
an important role triggering ocular inflammation by affecting to
the conjunctiva epithelial cells. Consequently, lowering its
presence by the administration of OA should result in a
diminished, or abrogated, ocular surface inflammation.
In our study we also demonstrated sPLA2-IIA- and allergen-
specific signals in eosinophils and mast cells, which are abolished
by the presence of OA. We focused on these cell-types because of
its significant contribution to the development of AC due to its
Figure 3. Effect of OA on cytokine and chemokine levels in EAC
mice. The cytokines IL-13, IL-33, IL-10 and sPLA2-IIA (A,B), as well as the
chemokines eotaxin and MCP-1 (C,D) were quantified in serum samples
(A,C) and ocular conjunctiva extracts (B,D) from mice of the indicated
groups 24 h after challenge. Results were expressed as the mean 6 SD
(n = 7/group). *P,0.001 vs control, and **P,0.001 vs untreated-EAC
mice.
doi:10.1371/journal.pone.0091282.g003
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Figure 4. Effect of OA on splenocyte functions. RWP-specific proliferative responses of splenic cells from untreated-EAC mice (A), and from mice
of the indicated groups (B). Cells were treated for 24 h with 50 mg/ml of RWP in presence or absence of the indicated doses of OA, and proliferation
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was measured. Each bar represents the mean 6 SD. (C and D) Quantification of IL-13, IL-33, and MCP-1 in supernatants from (A) and (B). Bars
represents means 6 SD. (n = 5). * and **P,0.001.
doi:10.1371/journal.pone.0091282.g004
Figure 5. OA abrogated in vitro biological functions on EoL-1 and RBL-2H3 cells. EoL-1 (A,C) and RBL-2H3 (B,D) cells were incubated with
the indicated stimuli in presence or absence of different concentrations of OA. (A,B) Cell proliferation was assayed 24 h after stimulation. (C,D) Cell
migration was measured as described in Materials and Methods. Bars represent means 6 SD. (*P,0.001 vs unstimulated cells; **P,0.001 vs stimuli
without triterpene; n = 3).
doi:10.1371/journal.pone.0091282.g005
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Figure 6. OA inhibits cell migration. EoL-1 (A) and RBL-2H3 (B) cells treated, or not, with 10 mM of OA for 30 min, were allowed to migrate as
described in Materials and Methods. Cell migration was assayed using eotaxin, RWP and sPLA2-IIA as schematically indicated by the green, red and
pink color, respectively. Bars represent means 6 SD. (*P,0.001 vs untreated control condition, and **P,0.001 vs stimuli without triterpene; n = 3).
doi:10.1371/journal.pone.0091282.g006
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cytotoxic and inflammatory effects by the release of their granule
proteins and the production of crucial inflammatory mediators.
We showed that sPLA2-IIA behaves as a chemoattractant for EoL-
1 eoshinophils and RBL-2H3 mast cells as potent as eotaxin, and
amplifies eotaxin-induced chemotaxis similarly to what is observed
with direct interaction of cells with RWP. These results are inline
with previous studies demonstrating cooperative chemotactic
responses between eotaxin and the cytokine IL-5 [44]. Thus,
suggesting that diverse inflammatory mediators, including sPLA2-
IIA, may act cooperatively to potentiate local chemotactic
responses. In addition, the phospholipase has been shown to
effectively trigger mast cell degranulation, and here we found that
it enhanced EoL-1 cells to undergo morphological differentiation
into mature eosinophil-like cells [45]. Interestingly, all the studied
responses were abolished in cells pretreated with OA. Therefore,
our data point to a critical role for sPLA2-IIA in the activity and
migratory capability into tissues of eosinophils and mast cells, and
a regulatory role for the triterpene OA in the prevention of cell
recruitment and activation. However, signaling pathways involved
in these events remain obscure and deserve a further and deeper
investigation.
In conclusion, OA seems to be a promising candidate for the
treatment of allergic eye disorders in addition to the conventional
therapies. It provided an effective treatment against the allergic
and immune-inflammatory responses in the EAC model. Thus,
the therapeutic potential for the treatment of allergic inflammatory
Figure 7. Effect OA on EoL-1 cell differentiation. EoL-1 cells were treated without and with 0.5 mM butyric acid, and 30 ng/ml of eotaxin, or
1 mg/ml sPLA2-IIA or 50 mg/ml RWP for 7 days, in absence (A) or presence of 5 mM OA (B). MBP expression was analyzed by Flow cytometry. In A, data
are expressed as the means of MFI 6 SD. *P,0.001 vs control cells, and **P,0.01 vs butyric acid-treated cells; n = 3. In B, histograms are
representative of three independent experiments: untreated (open black curves), stimulated (open dark grey curves) and OA+stimulated (open blue
curves). EoL-1 cells are compared with isotype controls (solid grey curves).
doi:10.1371/journal.pone.0091282.g007
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diseases such as allergic rhinitis and asthma should be also
considered. Further studies should also be directed to explore its
activity when administered topically.
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